Machine Learning Visionary, David Heckerman, Joins Human Longevity, Inc. as Chief Data Scientist
SAN DIEGO, CA, March 21, 2017 – Human Longevity, Inc., the genomics–powered, health intelligence company, announced today that David Heckerman, M.D., PhD., a 25-year veteran of Microsoft, has joined the company as the Chief Data Scientist. Dr. Heckerman, who will report to J. Craig Venter, Ph.D., HLI Co-founder, Executive Chairman and head of scientific strategy, will lead an advanced analytics team at HLI’s Mountain View, CA, office to continue to tackle some of the most important challenges in the analysis of large-scale medical and genomic data.
Dr. Heckerman’s many accomplishments as a Microsoft researcher include leading the company’s first research team to focus on machine learning and produce tools such as the first content-based spam filter. Later, he led the first research team to focus on computational biology, designing a vaccine for HIV as well as many algorithms for biology and health, with increasing emphasis over time on genomics. For the last several years, Heckerman has led the Microsoft Genomics team, advancing research in genomics and computational biology and supporting Microsoft cloud services for genomics.
“We are thrilled to have David onboard because his unparalleled expertise in machine learning, technical expertise in cloud computing, and extensive applications in genomics are going to be invaluable to HLI,” said Dr. Craig Venter, HLI Co-Founder and Executive Chairman. “David encompasses all the fields that are needed for success in the new landscape of data computing for medicine.”
Throughout his roles at Microsoft, Dr. Heckerman served in a series of academic positions, including Visiting Senior Research Scientist at the Data Science Institute of Columbia University, Affiliate Professor in the Department of Biomedical Informatics and Health Education at University of Washington, and Adjunct Professor at University of California, Los Angeles (UCLA). He holds several degrees from Stanford University and UCLA, including M.D., Ph.D. and M.S. in Computer Science from Stanford, and M.S. and B.S. in Physics, and B.S in Mathematics, from UCLA. He is an ACM and AAAI fellow.
“I am excited to join HLI as I believe my experiences in machine learning, genomics, and healthcare are ideal to help HLI in its next phases of growth and commercialization,” said Dr. Heckerman. “I look forward to leading and expanding the dynamic and expert team in our Mountain View office.”
HLI is building the world’s largest database of clinical, biological and behavioral information, including comprehensive genome and phenotype content curated with our proprietary computational tools by the leading experts in the field. As part of this effort, HLI is making data from over 10,000 genomes available to researchers through our Open Search tool, generating more insight into individual genomes through their comparison with many. HLI Open Search is an efficient, rapid, interactive way to explore genomic data and subsequent variant knowledge, created by HLI via a web-based search engine.
HLI is hiring experts in computational biology, quantitative genomics, biostatistics, bioinformatics, natural language processing, and machine learning to join the team in Mountain View and engage in genomics-powered, technology-driven innovations to generate health intelligence, including our HLI database and HLI Search data analysis services. Please visit our website to find out more about these positions.
About Human Longevity, Inc.™
Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ™ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.
Human Longevity, Inc. and MassMutual Sign Groundbreaking Agreement to Offer HLIQ™ Whole Genome Sequencing to MassMutual’s Customers, Financial Professionals and Employees
SAN DIEGO, Calif. and SPRINGFIELD, Mass. – March 15, 2017— Human Longevity, Inc. (HLI), the genomics-based, health intelligence company and Massachusetts Mutual Life Insurance Co. (MassMutual), announced today they have signed an innovative multi-year agreement to offer HLI’s whole genome sequencing product, HLIQ Whole Genome, to eligible MassMutual customers, employees and financial professionals at a reduced price. The initiative should help enable HLI’s goal of providing up to 200,000 HLIQ Whole Genome reports.
“MassMutual has long believed that both financial and physical health are important, inextricably linked components of individual well-being,” said Gareth Ross, MassMutual’s Chief Digital and Customer Experience Officer. “Our cutting-edge agreement with HLI – which is unlike anything else in our industry – may better enable our customers, employees and financial professionals to see the benefits of a long and healthy life.”
HLIQ Whole Genome, which is ordered by a client’s physician, includes comprehensive sequencing and analysis of the individual’s whole genome. The report may give insight into health status and risk for disease, details on which pharmaceuticals may work better for individuals, carrier status for family planning decisions, along with ancestry and personal traits. Clients and their doctors will receive an electronic version of the genome report and their entire genome in a printable poster format.
HLI’s data security standards are designed to fully protect client data. MassMutual will not receive from HLI any data, including genomic data, on these policyowners, customers, employees or financial professionals. MassMutual does not pay for or otherwise subsidize the cost of the HLIQ Whole Genome. This voluntary program is available to existing MassMutual customers as of March 14, 2017.
Cynthia Collins, HLI Chief Executive Officer stated, “Current practice of medicine is reactive, focused on management of disease and costly. The HLIQ Whole Genome is one of HLI’s novel solutions to help make healthcare more predictive, proactive, and preventative. We continue to believe that genomics will play an increasingly important role across a variety of business sectors including insurance and look forward to working with MassMutual.”
HLI has developed one of the world’s largest databases, which currently has approximately 40,000 genomes and related phenotype (physical trait) data. This distinct database, combined with HLI’s proprietary tools and machine learning capabilities, may enable HLI to make new discoveries from the genome, which could lead to more novel insights for customers. Clients also have the added benefit of knowing that their genomic data is helping to enhance the overall understanding of health and disease.
The offer is available through March 14, 2018.To learn more about HLIQ Whole Genome, customers should start by visiting MassMutual’s website at www.massmutual.com/HLI. More information about HLI and HLIQ Whole Genome can be found at www.humanlongevity.com.
About Human Longevity, Inc.™
Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.
MassMutual is a leading mutual life insurance company that is run for the benefit of its members and participating policy owners. MassMutual offers a wide range of financial products and services, including life insurance, disability income insurance, long term care insurance, annuities, retirement plans and other employee benefits. For more information, visit www.massmutual.com. MassMutual Financial Group is a marketing name for Massachusetts Mutual Life Insurance Company (MassMutual) and its affiliated companies and sales representatives.
HLI Media Contacts:
Heather Kowalski firstname.lastname@example.org, 858-361-0466
Katie McCormick Lelyveld, email@example.com, 858-249-7582
MassMutual Media Contact:
Michael McNamara, firstname.lastname@example.org, 413-744-3917
In Largest Whole Genome Sequence Analysis Study, Human Longevity, Inc.-Led Team Identifies Common-to-Rare Variants in the Human Blood Metabolome
The study shows the power of whole genome sequencing and analysis to uncover new variants missed in exome or genotyping arrays
(SAN DIEGO, CA)—March 6, 2017—Researchers from Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, have published results from the largest whole genome sequencing and analysis of blood metabolites. They were able to link 101 new sites in the genome to 246 metabolites and uncovered 90 rare variants that led to abnormal blood levels of certain metabolites. This work extends the known world of loci affecting the metabolome and highlights the surprising fact that there are more rare variants associated with abnormal blood metabolic phenotypes in adults than previously thought.
Human Longevity, Inc. Hires Cynthia Collins, Healthcare Industry Leader, as New Chief Executive Officer
Craig Venter, Ph.D., Co-founder and former CEO, will remain at Company as Executive Chairman and continue in full time role guiding scientific vision and strategy
(SAN DIEGO, CA)—January 4, 2017—Human Longevity, Inc. (HLI), the genomics-driven, health intelligence company, today announced Cynthia Collins as the new Chief Executive Officer effective January 9, 2017. Collins, who has a successful track record and extensive leadership experience in the life sciences sector, will lead HLI and be responsible for all functions of the company including commercialization of HLI key products and strategic operations. She will also join the Board of Directors.
Embracing the Perks of Cloud Computing
By Yaron Turpaz, Ph.D., MBA, CIO, Human Longevity, Inc.
Human Longevity, Inc. was launched in March 2014 with a mission to transform healthcare and accelerate the practice of personalized, preventive healthcare via detailed and comprehensive genomics analysis and risks assessment, in integration with high quality phenotypic and medical information. We have built the largest human genome sequencing facility in the world with 24 Illumina HiSeq X machines and two Pacific Bioscience instruments. With an unprecedented capacity to produce more than 30,000 whole human genomes per year, at 30X genome coverage, we have built an integrated KnowledgebaseTM and developed cloud based solutions to process, analyze and visualize such complex multi-dimensional data that provides time- sensitive meaningful scientific and personalized health insights. To date, we have processed more than 4PB of genomics data from more than 20,000 integrated genomes and health records, and are on track to have more than 1M integrated health records in our KnowledgebaseTM by 2020. This requires us to build solutions that support very large unstructured data sets with real time analysis of complex queries.
Researchers from Human Longevity, Inc. Publish Paper Detailing Results of Deep Sequencing of 10,545 Human Genomes
Paper outlines 150 million rare or unknown variants; approximately 8,500 novel variants per genome
Company also unveils new genome search engine, HLI Open Search, for beta testing
Human Longevity, Inc. Announces 10 Year Deal with AstraZeneca to Sequence and Analyze Patient Samples from AstraZeneca Clinical Trials
(SAN DIEGO, CA)—April 21, 2016—Human Longevity, Inc. (HLI), the genomics-based, technology-driven company working to revolutionize the practice of medicine, announced today a 10 year deal with AstraZeneca to sequence and analyze up to 500,000 DNA samples from AstraZeneca clinical trials. The genomic insights from the collaboration will be added to the HLI Knowledgebase™, building upon what is already the most comprehensive database of its kind. The deal was announced today at a press conference with AstraZeneca in Cambridge, UK. Financial terms of the deal were not disclosed.
StartUp Health Launches ‘Longevity Moonshot’ and Invests in Human Longevity, Inc. to Change Face of Aging
New York, NY (PRWEB)April 13, 2016 — StartUp Health, a global organization leading the movement to transform health by building the world’s largest community of Healthcare Transformers, today announced the launch of StartUp Health’s Longevity Moonshot, a mission to extend and enhance healthy life by 50+ years and change the face of aging. Marked by StartUp Health’s recent investment in Human Longevity, Inc (HLI), the genomics-based, technology-driven company led by co-founder and CEO J. Craig Venter, PhD., HLI was selected to be the founding partner of the Longevity Moonshot and become the 140th company to join StartUp Health’s exclusive Academy for Healthcare Transformers.
Human Longevity, Inc. Wins 2016 Bio-IT World Best Practice Award for the HLI Knowledgebase
Judges Honor Comprehensive Genome and Phenotype Database Curated with Proprietary Computational Tools by the Leading Experts in the Field
(SAN DIEGO, CA)—April 6, 2016—Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, has won the 2016 Bio-IT World Best Practice Award for its HLI Knowledgebase™, a key tool in the company’s portfolio to transform how medicine is practiced.